Bioinformatics and in vitro analysis reveals reduced SFRP4 expression correlates with poor prognosis in endometrial cancer, highlighting its protective tumor-suppressive role.
Uterine corpus endometrial cancer (UCEC) is one of the most common gynecologic cancers with rising global incidence. The aim of this study was to identify potential biomarker related to UCEC progression. Clinicopathologic data were obtained from other databases such as Gene Expression Omnibus (GEO), Genotype-Tissue Expression (GTEx), and The Cancer Genome Atlas (TCGA). The three GEO datasets were clustered to obtain differential genes. The differential gene Secreted Frizzled-Related Protein 4 (SFRP4) was screened and the relationship between SFRP4 expression and clinical features of UCEC was evaluated, and possible cellular mechanisms of SFRP4 in UCEC and the correlation between SFRP4 expression and immune infiltration were also explored. The mRNA and protein expression levels of SFRP4 were significantly lower in UCEC tissues than in noncancerous tissues. Multivariate Cox analysis and Kaplan–Meier survival analysis indicate that SFRP4 may have a protective effect in patients with UCEC.Real-time fluorescence quantitative PCR results showed that SFRP4 was lowly expressed in UCEC cell lines. In addition, SFRP4 expression is also associated with the tumor microenvironment (TME). SFRP4 may inhibit the progression of UCEC and could serve as a diagnostic or therapeutic biomarker with potential clinical applications.However, these findings require further validation.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: